| Cervical Cancer |
1 |
1 |
| Chemotherapy |
0 |
0.99 |
| Biologic Therapy |
0 |
0.59 |
| Cancer |
0 |
0.46 |
| Toxicology |
0 |
0.44 |
| Cornea and External Disease |
0 |
0.38 |
| Clinical Research |
0 |
0.98 |
| Conjunctivitis |
0 |
0.22 |
| Corneal Ulcer |
0 |
0.22 |
| Fatigue |
0 |
0.19 |
| Food and Drug Administration (FDA) |
0 |
0.97 |
| Orbit |
0 |
0.19 |
| Humanized Monoclonal Antibody |
0 |
0.16 |
| Dry Eye |
0 |
0.15 |
| Peripheral Neuropathy |
0 |
0.13 |
| Septic Shock |
0 |
0.13 |
| Adenocarcinoma |
0 |
0.09 |
| Alopecia |
0 |
0.09 |
| Angiogenesis Inhibitors |
0 |
0.09 |
| Antibody Drug Conjugates |
0 |
0.09 |
| Brachial |
0 |
0.09 |
| Central Sterile Corneal Ulceration |
0 |
0.09 |
| Conjunctiva |
0 |
0.09 |
| Epistaxis |
0 |
0.09 |
| Epithelium |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Hodgkin Lymphoma |
0 |
0.09 |
| Keratitis |
0 |
0.09 |
| Monoclonal Antibody |
0 |
0.09 |
| Nausea |
0 |
0.09 |
| Neuropathy |
0 |
0.09 |
| Neutropenia |
0 |
0.09 |
| Ophthalmic |
0 |
0.09 |
| Premedication |
0 |
0.09 |
| Sepsis |
0 |
0.09 |
| Shock |
0 |
0.09 |
| Skin and Soft Tissue Infection |
0 |
0.09 |
| Tissue |
0 |
0.09 |
| Tumor |
0 |
0.09 |